Is screening for thyroid carcinoma indicated in familial adenomatous polyposis?

被引：72

作者：

Bulow, C

Bulow, S

Berk, T

Bertario, L

Church, J

Evans, G

Neale, K

Park, JG

RodriguezBigas, M

SeowChoen, F

Vasen, H

Winde, G

机构：

[1] Danish Polyposis Register, Dept. of Surgical Gastroenterology, University of Copenhagen, Hvidovre

[2] Familial Gastrointest. Cancer R., Mount Sinai Hospital, Toronto, Ont.

[3] Italian Polyposis Registry, Milan, c/o A.I. Stom

[4] Familial Polyposis Registry, Cleveland Clinic Foundation, Cleveland, OH

[5] N. Western Region Polyposis Registry, St. Mary's Hospital, Manchester

[6] Polyposis Registry, St. Mark's Hospital, London

[7] Korean Polyposis Registry, Seoul National University Hospital, Seoul

[8] Familial Polyposis Registry, Roswell Park Cancer Institute, Buffalo, NY

[9] Singapore Polyposis Registry, Singapore General Hospital

[10] Dutch Polyposis Registry, University Hospital Leiden, Leiden

[11] Münster Polyposis Registry, University of Münster, Münster

[12] Dept. of Surgical Gastroenterology, Hvidovre Hospital, DK-2650 Hvidovre

来源：

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE | 1997年 / 12卷 / 04期

关键词：

D O I：

10.1007/s003840050097

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Forty-five polyposis patients with thyroid carcinoma constituted 1.2% of the patients in the Leeds Castle Polyposis Group database, The patients were diagnosed during 1959-1995: 44 were females at a median age of 25 years (range 10-40) and 37 (82%) had papillary carcinoma. At the end of 1995 only one patient (9%) had died from thyroid carcinoma, and the ten-year cumulative survival was 84% (95% confidence limits 72-97), Due to the low incidence of thyroid carcinoma in FAP and the good prognosis we do not recommend a regular thyroid screening in polyposis, as this is unlikely to result in a reduction of the mortality. but will only aggravate existing cancrophobia in these strained patients.

引用

页码：240 / 242

页数：3

共 14 条

[1] PAPILLARY THYROID-CARCINOMA ETIOLOGY, ASSESSMENT, AND THERAPY [J].